Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Liver Diseases

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 31 articles:
HTML format



Single Articles


    December 2025
  1. SCHOENFELD JD, Haas-Kogan DA, O'Neill AF
    Abscopal response in a patient with fibrolamellar hepatocellular carcinoma following radiotherapy.
    Lancet. 2025;404:2603-2604.
    PubMed    


    May 2025
  2. VITHAYATHIL M, Sharma R
    Nivolumab plus ipilimumab in hepatocellular carcinoma.
    Lancet. 2025 May 7:S0140-6736(25)00417-9. doi: 10.1016/S0140-6736(25)00417.
    PubMed    


  3. YAU T, Galle PR, Decaens T, Sangro B, et al
    Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
    Lancet. 2025 May 7:S0140-6736(25)00403-9. doi: 10.1016/S0140-6736(25)00403.
    PubMed     Abstract available


    February 2025
  4. RAHIM MN, Williamson C, Kametas NA, Heneghan MA, et al
    Pregnancy and the liver.
    Lancet. 2025;405:498-513.
    PubMed     Abstract available


    January 2025
  5. REITER FP, Geier A
    TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma.
    Lancet. 2025 Jan 8:S0140-6736(24)02680-1. doi: 10.1016/S0140-6736(24)02680.
    PubMed    


  6. SANGRO B, Kudo M, Erinjeri JP, Qin S, et al
    Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet. 2025 Jan 8:S0140-6736(24)02551-0. doi: 10.1016/S0140-6736(24)02551.
    PubMed     Abstract available


  7. KUDO M, Ren Z, Guo Y, Han G, et al
    Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
    Lancet. 2025 Jan 8:S0140-6736(24)02575-3. doi: 10.1016/S0140-6736(24)02575.
    PubMed     Abstract available


    November 2024
  8. ISRAELSEN M, Francque S, Tsochatzis EA, Krag A, et al
    Steatotic liver disease.
    Lancet. 2024;404:1761-1778.
    PubMed     Abstract available


    October 2024
  9. PONVILAWAN B, Roth MT
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1405.
    PubMed    


  10. QIN S
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial - Author's reply.
    Lancet. 2024;404:1405-1406.
    PubMed    


  11. WANG JK, Liao R
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1404-1405.
    PubMed    


  12. LI H, Yan J, Han T
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1403-1404.
    PubMed    


    September 2024
  13. ADAM R, Piedvache C, Chiche L, Adam JP, et al
    Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial.
    Lancet. 2024;404:1107-1118.
    PubMed     Abstract available


  14. HEINEMANN V, Stintzing S
    Liver transplantation in metastatic colorectal cancer: a new standard of care?
    Lancet. 2024;404:1078-1079.
    PubMed    


  15. TANAKA A, Ma X, Takahashi A, Vierling JM, et al
    Primary biliary cholangitis.
    Lancet. 2024;404:1053-1066.
    PubMed     Abstract available


    August 2024
  16. MAIWALL R, Kulkarni AV, Arab JP, Piano S, et al
    Acute liver failure.
    Lancet. 2024;404:789-802.
    PubMed     Abstract available


  17. CHOW PKH, Hack SP, Spahn JH, Yopp AC, et al
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial - Authors' reply.
    Lancet. 2024;404:657-658.
    PubMed    


  18. ROSE S, Ashraf MU, Premkumar M
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:656-657.
    PubMed    


  19. CHEN Z, Lan X, Du C, Xiao H, et al
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:656.
    PubMed    


  20. DONADON M, Di Martino M, Rigamonti C
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:655-656.
    PubMed    


  21. SHIN H, Lee JH
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:654-655.
    PubMed    


    June 2024
  22. ENG C, Yoshino T, Ruiz-Garcia E, Mostafa N, et al
    Colorectal cancer.
    Lancet. 2024 Jun 20:S0140-6736(24)00360-X. doi: 10.1016/S0140-6736(24)00360.
    PubMed     Abstract available


    May 2024
  23. DE OLIVEIRA FRANCO A, Uberti Dos Santos V, von Ameln Lovison O, Zavascki AP, et al
    Invasive liver abscess syndrome with central nervous system involvement caused by hypermucoviscous Klebsiella pneumoniae: positive string test.
    Lancet. 2024;403:2257-2258.
    PubMed    


    April 2024
  24. KARLSEN TH, Rutter H, Carrieri P, Zelber-Sagi S, et al
    The EASL-Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality.
    Lancet. 2024;403:1522-1524.
    PubMed    


    November 2023
  25. VON KODOLITSCH Y, Kubisch C, Carrel T
    AATD as a genetic risk factor for aneurysmal disease - Authors' reply.
    Lancet. 2023;402:1626.
    PubMed    


  26. KUEPPERS F
    AATD as a genetic risk factor for aneurysmal disease.
    Lancet. 2023;402:1625-1626.
    PubMed    


    October 2023
  27. VOGEL A, Meyer T, Saborowski A
    IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma.
    Lancet. 2023 Oct 23:S0140-6736(23)01962-1. doi: 10.1016/S0140-6736(23)01962.
    PubMed    


  28. QIN S, Chen M, Cheng AL, Kaseb AO, et al
    Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Oct 20:S0140-6736(23)01796-8. doi: 10.1016/S0140-6736(23)01796.
    PubMed     Abstract available


    September 2023
  29. PINATO DJ, D'Alessio A, Celsa C, Manfredi GF, et al
    The price and value of therapeutic synergy in liver cancer.
    Lancet. 2023;402:1108-1110.
    PubMed    


  30. TAPPER EB, Serper M
    Screening for advanced liver disease in the general population.
    Lancet. 2023;402:941-943.
    PubMed    


  31. SERRA-BURRIEL M, Juanola A, Serra-Burriel F, Thiele M, et al
    Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.
    Lancet. 2023;402:988-996.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.